27.73

2.78% 0.75

After Hours: 27.90 0.17 +0.61%

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $27.73, with a volume of 789.87K. It is up +2.78% in the last 24 hours and up +21.20% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$26.98

Open:

$27.11

24h Volume:

789.87K

Relative Volume:

1.16

Market Cap:

$2.06B

Revenue:

$105.97M

Net Income/Loss:

$-81.13M

P/E Ratio:

-25.70

EPS:

-1.0791

Net Cash Flow:

$-35.43M

1W Performance:

+3.82%

1M Performance:

+21.20%

6M Performance:

+48.93%

1Y Performance:

+153.47%

1-Day Range:

$26.91

$27.92

1-Week Range:

$25.83

$27.92

52-Week Range:

$10.69

$28.49

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2026-03-02

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	27.73	2.00B	105.97M	-81.13M	-35.43M	-1.0791
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Oct-24-25	Resumed	Wells Fargo	Equal Weight
Oct-14-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

03:57 AM

Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline strategy is suddenly worth a closer l - AD HOC NEWS

03:57 AM

05:03 AM

Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN

05:03 AM

04:56 AM

Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN

04:56 AM

Apr 14, 2026

How Investors Are Reacting To Zymeworks (ZYME) Elevating EcoR1 Veterans To Key Executive Roles - simplywall.st

Apr 14, 2026

Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline is suddenly worth a closer look - AD HOC NEWS

Apr 14, 2026

Zymeworks (ZYME) executive reports significant option and RSU awards - Stock Titan

Apr 10, 2026

Zymeworks (ZYME) EVP holds 167,000 options and 111,111 RSUs - Stock Titan

Apr 10, 2026

Apr 09, 2026

Zymeworks names Schayowitz as R&D head, Platshon as CBO By Investing.com - Investing.com Australia

Apr 09, 2026

Investment Recap: Should I average down on Zymeworks Inc stock2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn

Apr 09, 2026

Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 09, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - wahanariau.com

Apr 09, 2026

Zymeworks Bolsters Executive Team to Drive Next Phase of Growth - TipRanks

Apr 09, 2026

Zymeworks names Schayowitz as R&D head, Platshon as CBO - Investing.com

Apr 09, 2026

Zymeworks makes two interim leaders permanent to steer pipeline and deals - Stock Titan

Apr 09, 2026

Buybacks Report: Will Zymeworks Inc benefit from geopolitical trends2026 Intraday Action & Weekly Sector Rotation Insights - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Why Zymeworks (ZYME) Is Up 6.7% After FDA Fast Track Win And CFO Appointment - Sahm

Apr 08, 2026

Apr 07, 2026

Zymeworks (NASDAQ: ZYME) grants CFO large option and RSU awards - Stock Titan

Apr 07, 2026

Zymeworks (NASDAQ: ZYME) CFO reports zero beneficial share ownership - Stock Titan

Apr 07, 2026

Short Squeeze: Will Zymeworks Inc benefit from rising consumer demand2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME - MarketBeat

Apr 06, 2026

A Look At Zymeworks (ZYME) Valuation After Fast Track Win And New CFO Appointment - Sahm

Apr 06, 2026

Apr 04, 2026

ZYME PE Ratio & Valuation, Is ZYME Overvalued - Intellectia AI

Apr 04, 2026

ZYME Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Zymeworks Inc. R (ZA8.DU) Q1 FY2025 earnings call transcript - Yahoo Finance

Apr 03, 2026

Apr 02, 2026